Antonio Galeone

Antonio Galeone

Auto-generated profile, based on publicly available information

Antonio Galeone

Institute of Nanotechnology, National Research Council (CNR-NANOTEC), Lecce, 73100, Italy, Tecnomed Puglia - Tecnopolo per la medicina di precisione (Biotech Lecce Hub), 73100 Lecce, Italy

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 March 2026 in iScience
Verified
Journal Article
Open access
BMBruna My
Bruna My
ALAndrea Lia
Andrea Lia
LRLudovica Rizzo
Ludovica Rizzo
GMGabriele Maiorano
Gabriele Maiorano
AGAntonio Galeone
Antonio Galeone
GGGiuseppe Gigli
Giuseppe Gigli
CAR-T cell therapy has revolutionized the treatment of hematologic malignancies. Still, durable activity in tumors remains limited by antigen heterogeneity and escape, immunosuppressive tumor microenvironment, and restricted persistence. Genome engineering with CRISPR-Cas systems offers a powerful route to reprogram CAR-T cells; however, translation increasingly depends on how editing payloads are delivered. Viral vectors remain a benchmark for efficient gene transfer, cargo constraints, insertional risk, immunogenicity, and manufacturing complexity motivate the development of safer, more scalable non-viral platforms. In this review, we provide an overview of CAR designs, clinical use, and current ex vivo manufacturing workflow; compare viral and non-viral delivery routes while distinguishing established ex vivo editing from emerging in vivo T cell programming; and outline genome-engineering strategies organized by therapeutic goals. We highlight feasibility trade-offs and discuss how nanoparticles could enable transient, non-viral delivery of genome editors, while noting that robust T cell targeting and standardized potency/safety assays remain key bottlenecks.

30 June 2026 in Cell Reports
Verified
Journal Article
Open access
AGAntonio Galeone
Antonio Galeone
ESEmilio Solazzo
Emilio Solazzo
FLFrancesco Lavezzari
Francesco Lavezzari
SHSeung Yeop Han
Seung Yeop Han
GCGaia Consonni
Gaia Consonni
thomas vaccarithomas vaccari
thomas vaccari
Trimming of the three glucose residues decorating nascent N-glycoproteins is a critical step for their entry into the endoplasmic reticulum quality control (ERQC) and recognition by ER chaperones. However, the functional relevance of the second glucose (G2) and the regulatory step upstream of its removal by glucosidase II (GCS2) remain poorly understood. Here, we report that TUSC3, a component of the oligosaccharyltransferase (OST) complex, regulates G2 to G1 trimming on N-glycosylated bone morphogenetic protein 4 (BMP4) and its Drosophila homolog Dpp to promote their ERQC entry. Loss- and gain-of-function genetic experiments and biochemical assays in mammalian cells and flies indicate that TUSC3 serves as a dosage-sensitive gatekeeper that influences the decision between proper folding and secretion versus elimination by ER-associated degradation for the BMP4 molecules, thereby tuning BMP signaling. Together, these data reveal an unrecognized role for an OST component in early glycoprotein maturation, relevant to a major developmental signaling pathway.

24 April 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
MBMarta Biondi
Marta Biondi
AGAntonio Galeone
Antonio Galeone
CACorinne Arsuffi
Corinne Arsuffi
BMBruna My
Bruna My
EGErica Grassenis
Erica Grassenis
MSMarta Serafini
Marta Serafini
Chimeric Antigen Receptor (CAR) therapy for Acute Myeloid Leukemia (AML) is hindered by disease heterogeneity, antigen overlap with normal hematopoiesis, and the persistence of leukemic stem cells (LSCs). To overcome these barriers, we employed the IF-BETTER strategy to simultaneously target CD33 and the LSC-associated marker TIM-3 by pairing a second-generation CAR with a Cytokine-Costimulatory Receptor (CCR) in two dual CAR configurations (CD33.CAR/TIM-3.CCR and TIM-3.CAR/CD33.CCR). Both constructs displayed potent antigen-restricted cytotoxicity against AML cell lines and primary blasts, achieving leukemia clearance, while sparing normal immune and hematopoietic cells. Mechanistic studies revealed that the TIM-3.CAR single-chain fragment variable (scFv) recognizes a protein-proximal epitope whose interaction is selectively enhanced by AML-specific hyper-fucosylated and hyper-sialylated N-glycans. Fucosylation blockade reduced TIM-3.CAR avidity and cytotoxicity, confirming a glycosylation-modulated interaction. Integrating this glycosylation-tolerant TIM-3 scFv into a dual CAR framework enables selective targeting of AML cells, providing a rational strategy for safer and more effective AML-directed immunotherapy.

3 October 2025 in bioRxiv
Verified
Preprint
Open access
AGAntonio Galeone
Antonio Galeone
ESEmilio Solazzo
Emilio Solazzo
FLFrancesco Lavezzari
Francesco Lavezzari
SHSeung-Yeop Han
Seung-Yeop Han
BMBruna My
Bruna My
thomas vaccarithomas vaccari
thomas vaccari
SUMMARY: Trimming of the three glucose residues decorating nascent N -glycoproteins is a critical step for their entry into the endoplasmic reticulum quality control (ERQC) cycle and recognition by ER chaperones. However, the functional relevance of the second glucose (G2) and the regulatory step upstream of its removal by ER glucosidase II (GCS2) remains poorly understood. Here, we report that TUSC3, a component of the oligosaccharyltransferase (OST) complex, regulates G2 to G1 trimming on N- glycosylated bone morphogenetic protein 4 (BMP4) and its Drosophila homolog Dpp to promote their ERQC entry. Loss- and gain-of-function genetic experiments and biochemical assays in mammalian cells and flies indicate that TUSC3 serves as a dosage-sensitive gatekeeper that influences the decision between proper folding and secretion versus elimination by ER-associated degradation for BMP4 molecules, thereby tuning BMP signaling. Together, these data reveal an unrecognized role for an OST component in early glycoprotein maturation, relevant to a major developmental signaling pathway.